Articles tagged with Drug Targets
Dr. Sabine Ehrt takes the helm of microbiology and immunology at Weill Cornell Medicine, aiming to build on the department's reputation in tuberculosis research and expand into other areas. She seeks to foster cross-disciplinary collaborations and boost junior faculty mentorship.
Researchers developed a bispecific killer engager that selectively depletes PD-1 positive lymphocytes, a promising avenue for treating autoimmune diseases. The bike technology enhances NK cell-mediated apoptosis and depletion of activated immune cells, supporting its potential as a safe and potent tool.
Natasha Diba Sheybani, a UVA researcher, has received a $5.5 million grant to develop safer and more precise breast cancer treatments using focused ultrasound technology. Her work aims to overcome key bottlenecks in current treatments and improve patient outcomes.
Researchers used CRISPR interference to examine every gene in the human genome and discovered a new set of genes contributing to Parkinson's disease risk. The study identified the Commander complex, which regulates lysosomal function and is implicated in PD risk, offering opportunities for new treatments.
Researchers found that GSK3β becomes increasingly active in melanoma cells during treatment, helping them survive and adapt despite BRAF inhibitors. Treating resistant cancer cells with a GSK3β inhibitor significantly reduced their growth, suggesting blocking this protein could restore sensitivity to treatment.
A recent study found that people who use cannabis while drinking alcohol may experience fewer negative effects, potentially fueling more drinking. The study examined 6,334 data entries and found that participants perceived fewer negative impacts when using cannabis simultaneously with alcohol.
A new USC-led study using fMRI reveals the neural mechanisms that contribute to urinary incontinence in stroke survivors. The research found significant differences in brain activity during voluntary versus involuntary bladder contractions, presenting potential pathways for targeted therapies.
Researchers at St. Jude Children's Research Hospital have designed a new drug framework that selectively targets the CYP3A4 enzyme, reducing off-target effects. The discovery provides a roadmap for future drug developers to better evaluate drug interactions and selectively target CYP proteins.
Researchers developed a dual-action nanotherapy that converts white fat into beige fat and reduces obesity-related inflammation, significantly improving metabolic health without detectable toxicity.
The largest genome-wide association study on osteoarthritis identifies over 900 genetic associations, including 700 genes involved in the disease. These findings offer new insights into the genetic landscape of osteoarthritis and potential drug repurposing opportunities.
Researchers identified CSC characteristics, endogenous regulatory mechanisms, niche factors, and targeting strategies for digestive system tumors. Understanding CSCs is crucial for developing breakthrough treatments.
A team of scientists at the University of Florida has developed a new drug compound that selectively targets delta opioid receptors, providing pain relief without the dangerous side effects associated with opioids. The study's findings offer a promising approach to developing safer pain treatments, which could also be applied to treati...
Researchers at Mayo Clinic developed a personalized deep brain stimulation platform to treat drug-resistant epilepsy. The study found that this approach reduced seizures while also improving memory and sleep in patients with temporal lobe epilepsy.
Neuro-immunologist Stephen Hauser has won the 2025 Breakthrough Prize in Life Sciences for his role in identifying the immune system's primary driver of damage to nerve cells in multiple sclerosis. His B-cell theory has led to the development of therapies that have transformed treatment, reducing relapses and improving prognosis.
Researchers at Cornell University have discovered key neurological mechanisms in psilocybin's brain effects, targeting pyramidal tract neurons and serotonin receptors. This could enable pharmaceuticals to deliver mood-altering benefits while suppressing perceptual hallucinations.
Researchers developed a biosensor using an Amydetes vivianii firefly enzyme that detects pH changes in mammalian cells, which could be used to study diseases and assess drug toxicity. The technique is non-toxic and stable, providing a stronger glow than previous luciferases.
A new study reveals that specific gut bacteria can break down certain drugs, altering their efficacy. The research found that 30 out of 127 tested drugs were heavily metabolized by human gut microbiota, potentially reducing their effectiveness. The study's findings could have significant implications for personalized medicine and drug ...
Researchers discovered a mechanism that harnesses immune cells to produce opioids, potentially alleviating chronic pain. Estrogen and progesterone drive this process, which could lead to more effective treatments for women experiencing pain after menopause.
Aging (Aging-US) journal announces a commemorative collection honoring Dr. Mikhail Blagosklonny, a pioneer in aging biology. The special issue will explore key themes central to his scientific contributions, including mechanistic insights and translational approaches.
Researchers discovered senolytics can target Alzheimer's disease-associated brain enzymes AChE and BChE without affecting healthy ones. This selective approach may lead to safer treatments that improve memory and reduce inflammation in older adults.
A new study by researchers at McGill University found that annual COVID-19 vaccine booster doses help avoid breakthrough infections in people with immune-mediated inflammatory diseases. The study tracked 366 patients across Canada and used saliva PCR tests and antibody measurements, offering a more precise picture of infection risks.
Researchers developed new AI models, InstaNovo and InstaNovo+, to vastly improve accuracy and discovery in protein science. These models excel in tasks such as de novo peptide sequencing, identifying microorganisms, and discovering novel peptides, with implications for personalized medicine, cancer immunology, and beyond.
Researchers at Mayo Clinic are conducting a study to understand the factors that contribute to rapid progression of dementia in patients with Alzheimer's disease and Related Dementias. The team aims to identify biomarkers and disease-modifying targets that can improve diagnosis and treatment outcomes for these patients.
Researchers have identified six promising biomarkers that can detect drug-induced kidney injury earlier than traditional markers, enabling more timely monitoring during drug development. These biomarkers could lead to the development of safer medications and improve patient outcomes.
Researchers propose GLDH as a more liver-specific biomarker for detecting liver injury, offering greater specificity than current ALT and AST tests. The test performed similarly to ALT for detecting liver injury but was not impacted by associated muscle injury.
The C-Path-led initiative brought together clinical trial sponsors, eCOA technology providers, and regulators to identify and address eCOA implementation issues. Key resources developed during the initiative include guidance on COA data collection and a more open, collaborative environment.
The Weill Cancer Hub East will unite world-class experts in cancer biology, immunology, nutrition and metabolism to drive pioneering research. The hub aims to improve the effectiveness of immunotherapy, a promising approach for many types of cancers.
Researchers at the University of Houston College of Pharmacy have identified a potential therapeutic target to repair injured muscles. They discovered that fibroblast growth factor–inducible 14 (Fn14) plays a crucial role in regulating satellite cell stability and function, which are responsible for muscle growth, repair, and regenerat...
Many teenagers enter adulthood with significant risk factors for cardiovascular disease, and emerging adulthood is a key time to address these risks. Interventions such as health practices, lifestyle changes, and improved access to healthcare can help reduce the risk of developing future cardiovascular disease.
A new study found that treating aged mice with montelukast improved retinal health by reducing inflammation and boosting proteasome activity. This approach may offer a promising new way to slow age-related vision loss and protect eye health in older adults.
People with heart failure who can travel outside their home without assistance are less likely to be hospitalized or die within a year. Life-space mobility, a measure of how far patients move in their communities, is a reliable marker of risk for adverse outcomes in chronic diseases.
The University of Texas at Arlington has contributed 23 patents to UT System's total of 234, increasing by 15% over 2023. This recognition showcases the university's role in translating research into daily innovations.
A new review highlights how breast cancer cells change their communication and growth patterns, helping tumors survive, spread, and resist treatment. The review explores disrupted signaling pathways, including PI3K/Akt/mTOR and RAS/RAF/MEK/ERK, which can promote tumor progression and resistance to treatment.
Researchers have discovered a potential new treatment for pulmonary fibrosis by targeting the Piezo2 receptor, which plays a critical role in stiffness-mediated profibrotic fibroblast phenotypes. Inhibiting Piezo2 expression or function may slow disease progression and offer new therapeutic options.
A growing body of evidence suggests a significant link between human papillomavirus (HPV) and heart disease. Researchers pooled data from nearly 250,000 patients in seven studies, finding HPV-positive individuals had a 40% higher likelihood of developing cardiovascular disease.
A new drug therapy combination inhibiting FAK, RAF, and MEK enzymes has shown promise in prolonging survival rates for preclinical mouse models of metastatic melanoma. The study's findings suggest the oral treatment can both treat and prevent brain metastasis.
A recent study identifies 11 natural compounds that can inhibit the SARS-CoV-2 spike protein, including caffeine, which exhibits high binding stability and excellent solubility. The discovery highlights the potential of natural products in combating COVID-19 and demonstrates the versatility of widely known compounds like caffeine.
The Alliance for Genomic Discovery has completed sequencing 250,000 whole genomes, providing a comprehensive clinical genomic dataset. This data is being leveraged to accelerate drug target discovery and therapeutic research.
Researchers at the University of Zurich have developed a technology to test 25 antibodies simultaneously in a single mouse, greatly reducing the number of laboratory animals required. The method uses protein fragments as barcodes for analysis, allowing for high-quality preclinical data on multiple antibody candidates.
The study found that tunneling nanotube-like structures connect cells in the heart, enabling long-distance intercellular communication essential for heart formation. Disruption of these structures resulted in impaired ventricular wall morphogenesis and defective myocardial growth.
Tirzepatide and semaglutide offer substantial long-term health benefits in US adults, reducing obesity risk. However, the high costs of these medications make them not cost-effective at current net prices, hindering equitable access.
Cyclic peptides targeting FXR show promise in treating MASH by reducing intestinal ceramide production and promoting GLP-1 release. DC646 is the most potent FXR antagonist with a favorable safety profile.
Researchers have discovered how severe COVID-19 can destroy immune cells' ability to repair the lungs, leading to lingering effects of long COVID. By enhancing damaged organelles using a FDA-approved drug, they found improved lung healing and reduced inflammation.
Engineered platelets-based nano-aircraft carriers enhance targeted chemotherapy with graded drug release, promoting antitumor immune response and reducing metastasis. Researchers successfully develop Pts-based nanovesicles for precise cancer treatment.
A new type of antibody that stimulates the immune system to target cancer cells has shown promise in reducing tumor growth in treatment-resistant breast and ovarian cancers. The study found that the antibody, IgE, uniquely stimulated otherwise inactive immune cells to directly target HER2-expressing cancer cells.
The Crew-10 mission will support cutting-edge biomedical investigations and NSF-funded physical science projects through the ISS National Lab. Astronauts will conduct experiments on the International Space Station, with findings benefiting humanity and driving commerce in low Earth orbit.
Research from the Long Life Family Study found individuals from long-lived families have significantly better vascular health than the general population. The study identified key risk factors and four genomic regions linked to PAD risk, providing novel insight into underlying mechanisms.
Researchers used CRISPR to cut a single gene from cancer cells of head and neck tumors, resulting in the elimination of 50% of the tumors after 84 days. This groundbreaking study demonstrates that some genes are essential for cancer cell survival, making them excellent targets for CRISPR therapy.
Researchers at Weill Cornell Medicine and MIT discovered a family of genes necessary for tuberculosis bacteria to survive airborne transmission. These genes help the bacteria adapt to changes in temperature, oxygen levels, and humidity, providing new targets for therapies that could treat infection and prevent spread.
Researchers have discovered a family of genes essential for tuberculosis survival during airborne transmission, providing new drug targets. The study sheds light on the bacterium's protective mechanisms, which could prevent infection spread and treat existing cases.
Researchers at Vanderbilt University Medical Center aim to use artificial intelligence technologies to generate antibody therapies against specific antigen targets. The project, funded by $30 million from ARPA-H, will create a massive antibody-antigen atlas and develop AI-based algorithms to engineer antigen-specific antibodies.
Magnetic nanoparticles are guided to tumors using a magnet and heated by a laser to destroy cancer cells. Researchers developed nanoparticles that outperform conventional photothermal agents, killing cancer cells with high efficiency.
A new study by researchers at UCSF has found that long-acting injectable treatments can be transformative for patients who struggle to take daily HIV pills, resulting in undetectable viral loads and improved health outcomes. The treatment approach could help stop the spread of HIV by keeping more patients from being infectious.
Core-shell nanoparticles offer effective drug encapsulation, shielding from degradation, and controlled release. This innovation enables targeted drug delivery, improving treatment outcomes and reducing side effects. The versatility of these nanoparticles allows for tailored materials to suit different therapeutic needs.
The Aligning Science Across Parkinson’s (ASAP) initiative offers funding of up to $6M for research community members to develop sustainable tools for Parkinson’s disease research. The funding supports the development of preclinical models, detection reagents, and modulation agents to accelerate therapeutic research.
The new AI model leverages hypergraphs to quickly and accurately identify therapeutic gene targets for diseases. HIT outperformed existing models in all tested metrics, demonstrating its accuracy in classifying therapeutic gene targets with great precision.
Researchers at VCU Massey Comprehensive Cancer Center have identified an innovative combination treatment strategy that collaborates to kill AML cells. The new approach targets the SRC gene and MCL-1 protein, leading to increased cell death in leukemia cells. This discovery offers a promising new direction for leukemia treatment.
The FDA has approved a new treatment for Parkinson's disease that can adjust to the individual's brain activity, providing precise stimulation. This technology, known as adaptive deep brain stimulation (aDBS), detects patterns of brain activity and delivers tailored electric pulses to reduce symptoms.
Researchers explore ataciguat to manage aortic valve stenosis, showing potential to significantly slow disease progression. The drug may enable a once-in-a-lifetime procedure by delaying valve replacement surgery.
Researchers have discovered several novel downstream p53 targets that could lead to improved cancer therapies. The study highlights the critical role of p53 in preventing cancer and identifies two new genes, ALDH3A1 and NECTIN4, as potential targets for cancer treatment.